Search

Your search keyword '"Ma, Jianqun"' showing total 172 results
Start Over Author "Ma, Jianqun"
172 results on '"Ma, Jianqun"'

1. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial

Author

Qin, Jianjun, Xue, Liyan, Hao, Anlin, Guo, Xiaofeng, Jiang, Tao, Ni, Yunfeng, Liu, Shuoyan, Chen, Yujie, Jiang, Hongjing, Zhang, Chen, Kang, Mingqiang, Lin, Jihong, Li, Hecheng, Li, Chengqiang, Tian, Hui, Li, Lin, Fu, Junke, Zhang, Yong, Ma, Jianqun, Wang, Xiaoyuan, Fu, Maoyong, Yang, Hao, Yang, Zhaoyang, Han, Yongtao, Chen, Longqi, Tan, Lijie, Dai, Tianyang, Liao, Yongde, Zhang, Weiguo, Li, Bin, Chen, Qixun, Guo, Shiping, Qi, Yu, Wei, Li, Li, Zhigang, Tian, Ziqiang, Kang, Xiaozheng, Zhang, Ruixiang, Li, Yong, Wang, Zhen, Chen, Xiankai, Hou, Zhiguo, Zheng, Rongrong, Zhu, Wenqing, He, Jie, and Li, Yin

Published
2024
Full Text
View/download PDF

7. CACA guidelines for holistic integrative management of esophageal carcinoma

Author

Gong, Lei, Bai, Ming, Dai, Liang, Guo, Xufeng, Leng, Xuefeng, Li, Zhigang, Lu, Zhihao, Mao, Teng, Pang, Qingsong, Shen, Lin, Sun, Yifeng, Yang, Hong, Yin, Jun, Zhang, Hongdian, Zhang, Wencheng, Zhao, Gang, Zheng, Bin, Yang, Yueyang, Ba, Yi, Chen, Chun, Chen, Haiquan, Chen, Longqi, Deng, Ting, Fan, Qingxia, Fang, Wentao, Fu, Xiangning, Huang, Jing, Li, Xiaofei, Li, Yin, Liu, Shuoyan, Liu, Yongyu, Ma, Jianqun, Mao, Weimin, Ren, Jingli, Tan, Lijie, Tang, Peng, Wang, Lvhua, Wang, Qun, Wei, Wenqiang, Xue, Qi, Zhang, Renquan, Chen, Keneng, Fu, Jianhua, Liu, Junfeng, Han, Yongtao, He, Jie, Yu, Zhentao, and Mao, Yousheng

Published
2023
Full Text
View/download PDF

11. Minimally invasive versus open esophagectomy for resectable thoracic esophageal cancer (NST 1502): a multicenter prospective cohort study

Author

Mao, Yousheng, Gao, Shugeng, Li, Yin, Chen, Chun, Hao, Anlin, Wang, Qun, Tan, Lijie, Ma, Jianqun, Xiao, Gaoming, Fu, Xiangning, Fang, Wentao, Li, Zhigang, Han, Yongtao, Chen, Keneng, Zhang, Renquan, Li, Xiaofei, Rong, Tiehua, Fu, Jianhua, Liu, Yongyu, Mao, Weimin, Xu, Meiqing, Liu, Shuoyan, Yu, Zhentao, Zhang, Zhirong, Fang, Yan, Fu, Donghong, Wei, Xudong, Yuan, Ligong, Muhammad, Shan, and He, Jie

Published
2023
Full Text
View/download PDF

16. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.

Author

Li, Yin, primary, Qin, Jianjun, additional, Xue, Liyan, additional, Hao, Anlin, additional, Jiang, Tao, additional, Liu, Shuoyan, additional, Jiang, Hongjing, additional, Kang, Mingqiang, additional, Li, Hecheng, additional, Tian, Hui, additional, Fu, Junke, additional, Ma, Jianqun, additional, Fu, Maoyong, additional, Han, Yongtao, additional, Chen, Longqi, additional, Tan, Lijie, additional, Dai, Tianyang, additional, Liao, Yongde, additional, Zhang, Weiguo, additional, and Li, Bin, additional

Published
2024
Full Text
View/download PDF

18. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study)

Author

Yang, Yingnan, primary, Zhang, Jinfeng, additional, Meng, Hongxue, additional, Ling, Xiaodong, additional, Wang, Xiaoyuan, additional, Xin, Yanzhong, additional, Jiang, Hao, additional, Zhang, Luquan, additional, Fang, Chengyuan, additional, Liang, Hao, additional, Ma, Jianqun, additional, and Zhu, Jinhong, additional

Published
2023
Full Text
View/download PDF

26. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment

Author

Wang, Xiaoyuan, primary, Ling, Xiaodong, additional, Wang, Changhong, additional, Zhang, Jinfeng, additional, Yang, Yingnan, additional, Jiang, Hao, additional, Xin, Yanzhong, additional, Zhang, Luquan, additional, Liang, Hao, additional, Fang, Chengyuan, additional, Zheng, Dayong, additional, Zhu, Jinhong, additional, and Ma, Jianqun, additional

Published
2022
Full Text
View/download PDF

31. 405 Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): a phase II, single-arm, exploratory research

Author

Ma, Jianqun, primary, Zhang, Jinfeng, additional, Yang, Yingnan, additional, Zheng, Dayong, additional, Wang, Xiaoyuan, additional, Liang, Hao, additional, Zhang, Luquan, additional, Xin, Yanzhong, additional, Ling, Xiaodong, additional, Fang, Chengyuan, additional, Jiang, Hao, additional, Meng, Hongxue, additional, and Zheng, Wei, additional

Published
2021
Full Text
View/download PDF

32. 406 Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: a phase II, single-arm, exploratory research

Author

Ma, Jianqun, primary, Zhang, Jinfeng, additional, Yang, Yingnan, additional, Zheng, Dayong, additional, Wang, Xiaoyuan, additional, Liang, Hao, additional, Zhang, Luquan, additional, Xin, Yanzhong, additional, Ling, Xiaodong, additional, Fang, Chengyuan, additional, Jiang, Hao, additional, and Zheng, Wei, additional

Published
2021
Full Text
View/download PDF

34. A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study)

Author

Duan, Hongtao, primary, Wang, Tianhu, additional, Luo, Zhilin, additional, Wang, Xiaoyuan, additional, Liu, Honggang, additional, Tong, Liping, additional, Dong, Xiaoping, additional, Zhang, Yong, additional, Valmasoni, Michele, additional, Kidane, Biniam, additional, Almhanna, Khaldoun, additional, Wiesel, Ory, additional, Pang, Sainan, additional, Ma, Jianqun, additional, and Yan, Xiaolong, additional

Published
2021
Full Text
View/download PDF

35. Prognostic and Immunological Implications of FAM72A in Pan-Cancer and Functional Validations.

Author

Bai, Yuwen, Cao, Kui, Zhang, Ping, Ma, Jianqun, and Zhu, Jinhong

Subjects
PROGNOSIS, RECEIVER operating characteristic curves, IMMUNE checkpoint proteins, ONCOGENES, CELL migration, IMMUNE response
Abstract

The family with sequence similarity 72 Member A (FAM72A) is overexpressed in several types of cancer. However, its contributions to tumorigenesis remain largely unknown. Based on The Cancer Genome Atlas (TCGA) database, FAM72A was upregulated across 33 types of cancer. Accordingly, high levels of FAM72A predicted inferior outcomes in half of the cancer types using survival analysis (the Kaplan-Meier curve and univariate Cox regression model). Receiver operating characteristic (ROC) analysis demonstrated that FAM72A showed high accuracy in distinguishing cancerous tissues from normal ones. FAM72A was correlated with immune and stromal scores and immune cell infiltrations in various tumors. Moreover, FAM72A was also associated with tumor mutation burden (TMB), microsatellite instability (MSI), and immune checkpoint genes. Immunophenoscore (IPS) further validated that the FAM72Alow tumor showed high immunogenicity and tended to respond to anti-PD1/PDL1/PDL2, anti-CTLA4 treatment, and combined immunotherapies. We also investigated the functional role of FAM72A in lung adenocarcinoma (LUAD). In vitro studies demonstrated that the ectopic expression of FAM72A accelerated the proliferation and migration of NSCLC cells, whereas silencing FAM72A showed the opposite effects on them. In short, FAM72A had prognostic potential and correlated with tumor immunogenicity in various tumors. Functional analysis indicated that FAM72A is an oncogene in LUAD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China.

Author

Yang, Yang, Tan, Lijie, Hu, Jian, Li, Yin, Mao, Yousheng, Tian, Ziqiang, Zhang, Baihua, Ma, Jianqun, Li, Hecheng, Chen, Chun, Chen, Keneng, Han, Yongtao, Chen, Longqi, Liu, Junfeng, Yu, Bentong, Yu, Zhentao, Li, Zhigang, and Association, the Esophageal Cancer Committee of Chinese Anti-Cancer

Subjects
IMMUNOTHERAPY, IMMUNE checkpoint inhibitors, ESOPHAGEAL cancer, NEOADJUVANT chemotherapy, IPILIMUMAB, DRUG side effects, TREATMENT effectiveness
Abstract

Immune checkpoint inhibitors (ICIs) have shown a powerful benefit in the neoadjuvant therapy for esophageal cancer, but evidence for its safety and efficacy is limited and may not reflect real-world practice. We retrospectively reviewed the database of treatment-naive patients from 15 esophageal cancer centers in China who received ICIs as neoadjuvant treatment for locally advanced esophageal cancer from May 2019 to December 2020. The primary endpoints were rate and severity of treatment-related adverse events (TRAEs) and immune-related adverse events (irAEs). Secondary endpoints included pathologically complete response (pCR) rate, R0 resection rate, mortality and morbidity. Among the 370 patients, 311 (84.1%) were male with a median age of 63 (range: 30–81) years and stage III or IVa disease accounted for 84.1% of these patients. A total of 299 (80.8%) patients were treated with ICIs and chemotherapy. TRAEs were observed in 199 (53.8%) patients with low severity (grade 1-2, 39.2%; grade 3-4, 13.2%; grade 5, 1.4%), and irAEs occurred in 24.3% of patients and were mostly of grade 1-2 severity (21.1%). A total of 341 (92.2%) patients had received surgery and R0 resection was achieved in 333 (97.7%) patients. The local pCR rate in primary tumor was 34.6%, including 25.8% of ypT0N0 and 8.8% of ypT0N+. The rate of postoperative complications was 41.4% and grade 3 or higher complications occurred in 35 (10.3%) patients. No death was observed within 30 days after surgery, and three patients (0.9%) died within 90 days postoperatively. This study shows acceptable toxicity of neoadjuvant immunotherapy for locally advanced esophageal cancer in real-world data. Long-term survival results are pending for further investigations. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. 2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer

Author

Kang, Xiaozheng, primary, Qin, Jianjun, additional, Zhang, Ruixiang, additional, Wang, Zhen, additional, Zheng, Qingfeng, additional, Li, Yong, additional, Xu, Jianping, additional, Huang, Jing, additional, Wang, Xin, additional, Hui, Zhouguang, additional, Xue, Liyan, additional, Mao, Yousheng, additional, Li, Yin, additional, He, Jie, additional, Chen, Chun, additional, Chen, Haiquan, additional, Chen, Ke-Neng, additional, Chen, Long-Qi, additional, Fu, Maoyong, additional, Fu, Junke, additional, Geng, Qing, additional, Gong, Taiqian, additional, Guo, Shiping, additional, Han, Yongtao, additional, He, Yi, additional, Hu, Jian, additional, Jiang, Hongjing, additional, Jiang, Jie, additional, Jiang, Yuequan, additional, Kang, Mingqiang, additional, Ma, Jianqun, additional, Ma, Shaohua, additional, Liao, Yongde, additional, Li, Hecheng, additional, Li, Shanqing, additional, Li, Zhigang, additional, Liu, Shuoyan, additional, Liu, Yang, additional, Qiao, Guibin, additional, Tan, Lijie, additional, Tian, Hui, additional, Zhao, Gaofeng, additional, Zhao, Jun, additional, Zheng, Shiying, additional, Zhou, Yongan, additional, Nilsson, Magnus, additional, Schlottmann, Francisco, additional, Rosati, Riccardo, additional, Stefano, Cascinu, additional, Chiu, Philip Wai-yan, additional, Newman, Neil B., additional, Hirahara, Noriyuki, additional, Kim, Dae Joon, additional, Mehta, Rutika, additional, Johung, Kimberly L., additional, Cecchini, Michael, additional, Lloyd, Shane, additional, and Meredith, Kenneth, additional

Published
2021
Full Text
View/download PDF

42. Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase Ⅱ, single-arm, exploratory research.

Author

Ma, Jianqun, primary, Zhang, Jinfeng, additional, Yang, Yingnan, additional, Zheng, Dayong, additional, Wang, Xiaoyuan, additional, Liang, Hao, additional, Zhang, Luquan, additional, Xin, Yanzhong, additional, Ling, Xiaodong, additional, Fang, Chengyuan, additional, Jiang, Hao, additional, and Zheng, Wei, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results